Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA registry

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 71-80

  Schaefer, Juergen R ^a   Gitt, Anselm K ^b   Sonntag, Frank ^c   Weizel, Achim ^d   Jannowitz, Christina ^e   Karmann, Barbara ^e   Pittrow, David ^f   Bestehorn, Kurt ^f  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Vorsitzender der DGFF ^*

^d Vorsitzender der DGFF   (Germany)

^e MSD Sharp and Dohme GmbH   (Germany)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cardiovascular disease; Coronary heart disease; Dyslipidemia; Observation; Risk factors; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL ABSORPTION INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; SIMVASTATIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; DEATH; DIABETES MELLITUS; DIALYSIS; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GERMANY; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTPATIENT DEPARTMENT; PROSPECTIVE STUDY; REGISTER; RISK FACTOR;

EID: 84879163602     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S37143     Document Type: Article

References (36)

1. World Health Organization. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008. Available from: http://www. who.int/healthinfo/global_burden_disease/2004_report_update/en/index. html. Accessed September 13, 2012.
2. Centers for Disease Control and Prevention (CDC). QuickStats: Age-adjusted death rates for heart disease and cancer - United States, 1999 - 2009*. MMWR [series on the Internet]. Jun 2011;60(21):713. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm6021a6.htm?s_cid=mm6021a6_w. Accessed November 28, 2012.
3. Goldstein LB, Adams R, Alberts MJ, et al. Primary prevention of ischemic stroke. A guideline from the American Heart Association/ American Stroke Association Stroke Council:Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affrms the value of this guideline. Stroke. 2006;37(6):1583-1633.
4. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive summary. A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2010;56(25):2182-2199.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
6. Klose G, Schwabe U. Lipidsenkende Mittel. [Lipid lowering drugs]. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs-Report 2011. Berlin: Springer; 2010:683-698. German.
7. Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-834.
8. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA. 1999;282(15):1458-1465.
9. Bestehorn K, Schäfer J, Gitt A, et al. Leitliniengerechte Lipidtherapie und Zielwerterreichung bei Risikopatienten im klinischen Alltag. Rationale, Ziele und Design des LIMA-registers [LIMA-register: rationale, aims and design]. MMW Fortschr Med. 2008;150(Suppl 3): S135-S141. German.
10. Sonntag F, Schaefer JR, Gitt AK, et al. Lipidtherapie im Alltag (LIMA): Leitliniengerechtes Lipidmanagement bei Patienten mit hohem kardiovaskulären Risiko in der klinischen Praxis (LIMA Register) [Lipid therapy in daily routine. Guidelines compatible lipid management of patients with high cardiovascular risk in clinical practice (LIMA registry)]. Dtsch med Wochenschr. 2012;137(40):2047-2052. German.
11. Good Epidemiological Practice (GEP): Proper conduct in epidemiologic research. Updated 2007. International Epidemiological Association; 2007 [updated April 24, 2010]. Available from: http://ieaweb.org/2010/ 04/good-epidemiological-practice-gep/. Accessed November 28, 2012.
12. Norgren L, Hiatt WR, Dormandy JA, et al; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1: S1-S75.
13. Gitt AK, Jünger C, Smolka W, Bestehorn K. Prevalence and overlap of different lipid abnormalities in statin-treated patients at high cardiovascular risk in clinical practice in Germany. Clin Res Cardiol. 2010; 99(11):723-733.
14. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.
15. Baigent C, Keech A, Kearney PM, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Effcacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
16. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423-1427.
17. Lee JMS, Choudhury R P. Prospects for atherosclerosis regression through increase in high-density lipoprotein and other emerging therapeutic targets. Heart. 2007;93(5):559-564.
18. Gitt AK, Juenger C, Jannowitz C, Karmann B, Senges J, Bestehorn K. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry. Eur J Cardiovasc Prev Rehabil. 2009;16(4): 438-444.
19. Sager HB, Linsel-Nitschke P, Mayer B, et al. Physicians' perception of guideline-recommended low-density lipoprotein target values: characteristics of misclassifed patients. Eur Heart J. 2010;31(10):1266-1273.
20. Hayward RA, Krumholz HM. Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institute of Health. Circ Cardiovasc Qual Outcomes. 2012;5(1):2-5.
21. Buyken AE, von Eckardstein A, Schulte H, Cullen P, Assmann G. Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil. 2007;14(2):230-236.
22. Saely CH, Aczel S, Koch L, et al. Diabetes as a coronary artery disease risk equivalent: before a change of paradigm? Eur J Cardiovasc Prev Rehabil. 2010;17(1):94-99.
23. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med. 2009;26(2):142-148.
24. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation. 2008;117(15):1945-1954.
25. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage J, Bowman L, Wallendszus K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010;376(9753):1658-1669.
26. FDA: Limit use of 80 mg simvastatin. US Food and Drug Administration;2011 [updated June 8, 2011]. Available from: http:// www.fda.gov/ForConsumers/ConsumerUpdates/ucm257884.htm. Accessed November 28, 2012.
27. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999; 341(7):498-511.
28. FDA drug safety communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. US Food and Drug Administration; 2011 [updated June 8, 2011]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm256581. htm. Accessed November 28, 2012.
29. Mikhailidis D P, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin. 2011;27(6):1191-1210.
30. Zeymer U, Dechend R, Deeg E, et al; 3A Registry Investigators. Aliskiren for the treatment of essential hypertension under real-life practice conditions: design and baseline data of the prospective 3A registry. Int J Clin Pract. 2012;66(3):251-261.
31. Zeymer U, Senges J, Parhofer KG, Röther J. Risk factors and event rates in patients with atherothrombotic disease in Germany: Results of the REACH registry. Dtsch Arztebl Int. 2008;105(45):769-775.
32. Ijioma N, Robinson JG. Lipid-lowering effects of ezetimibe and simvastatin in combination. Expert Rev Cardiovasc Ther. 2011;9(2): 131-145.
33. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med. 2005;165(10):1147-1152.
34. Pittrow D, Stalla GK, Zeiher AM, et al. Prävalenz, medikamentöse Behandlung und Einstellung des Diabetes mellitus in der Hausarzt-praxis. [Prevalence, drug treatment and metabolic control of diabetes mellitus in primary care]. Med Klin (Munich). 2006;101(8):635-644. German.
35. Bestehorn K, Jannowitz C, Karmann B, Pittrow D, Kirch W. Characteristics, management and attainment of lipid target levels in diabetic and cardiac patients enrolled in Disease Management Program versus those in routine care: LUTZ registry. BMC Public Health. 2009; 9:280.
36. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749-754.